Antibacterial drugs
Overview
This report looks at prescribing trends in primary care for Antibacterial drugs at SICBl and ICB level with particular focus on prescribing volume of antibacterial agents such as cephalosporins, quinolones, macrolides and tetracyclines. Prescribing data is weighted with STAR-PU prescribing measures, and incorporates C. difficile rates and non-medical prescribing.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
January 2020 to December 2022
Prescribing Update Newsletter – May 2022
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition covers how the RDTC can support stakeholder organisations, our recent publications, and the prescribing support workplan. It also has features on post exposure prophylaxis for chickenpox and shingles, the national flu immunisation programme 2022-23, inadvertent oral administration of potassium permanganate, the CVD eLearning programme, WHO changes to the treatment of drug-resistant tuberculosis, and sources of information on menopause and HRT availability.
Antimicrobial prescribing across the North of England
This bulletin provides an update on the current primary care antimicrobial prescribing trends at ICS level in the North of England. It specifically focuses on primary care prescribing, including the top 10 antibacterial drugs prescribed and the variation in the proportion of broad spectrum antibacterials prescribed across the ICSs.
Brolucizumab for wet age-related macular degeneration
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Brolucizumab is a monoclonal antibody specific for vascular endothelial growth factor (VEGF). It is indicated for treatment of wet age-related macular degeneration (AMD), and is administered as an intravitreal injection every eight or 12 weeks.
Download the full review below to read more.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation
Antibiotic use in children: liquid vs. solid oral dosage forms
This bulletin addresses cost-effective prescribing of oral antimicrobials in children without dysphagia. Liquid antimicrobial preparations are significantly more expensive than solid oral dosage forms, so the bulletin aims to
present the current prescribing patterns of antimicrobial formulations in the paediatric population on a CCG Level.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
There are three versions of this publication; please select the appropriate version for your region below.